科尔奇辛可以预防心房缩后复发:系统性审查和元分析
Hritvik Jain1, Ramez M Odat2, Debankur Dey3
1From the Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, India.
Cardiology in review
|August 28, 2024
概括
对于心房动 (AF) 的导管切除后使用素可以减少AF的复发,但会增加胃肠道的副作用. 需要进一步的研究来优化其使用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医学研究 医学研究
背景情况:
- 导管切除是对心房动 (AF) 的常见治疗方法.
- 切除后的AF复发是一个重大的临床挑战,通常与炎症和氧化应激有关.
- 抗炎药物科尔奇辛在切除后预防AF复发方面表现异常.
研究的目的:
- 为了评估胆固醇在预防心房动复发后导管切除后的疗效.
- 评估黄素的安全性,包括胃肠道问题和心周炎等副作用.
主要方法:
- 在主要的文献数据库中进行了全面的文献搜索.
- 六项涉及1791名患者的研究 (721名接受了菌素治疗,1070名接受了安慰剂治疗) 被纳入了分析.
- 几率比率 (ORs) 和95%置信区间 (CI) 使用随机效应模型进行了聚合.
主要成果:
- 素显著降低了AF复发的几率 (OR,0.62;P = 0.0001).
- 胃肠道副作用在素组显着更高 (OR,2.67;P = 0.05).
- 两组之间在急性心膜炎或住院率方面没有发现显著差异.
结论:
- 在AF导管切除后,预防性使用胆固醇可以降低复发率.
- 胃肠道副作用的增加与使用科尔奇辛有关.
- 需要进一步进行大规模随机对照试验,以确定最佳剂量和持续时间,以确保有效性和安全性.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
936
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
936
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
799
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
799
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501


